{"id":80,"date":"2020-04-23T09:27:01","date_gmt":"2020-04-23T09:27:01","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=80"},"modified":"2020-05-12T05:33:53","modified_gmt":"2020-05-12T05:33:53","slug":"15-april-2020-favipiravir-significantly-improved-latency-to-relief-for-pyrexia-and-cough","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/15-april-2020-favipiravir-significantly-improved-latency-to-relief-for-pyrexia-and-cough\/","title":{"rendered":"(15 April 2020) Favipiravir- significantly improved  latency to relief for pyrexia and cough"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.17.20037432v4<\/p>\n<p class=\"\">In a prospective, randomized, controlled, open-label multicenter trial involving 240 adult patients with COVID-19. Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7. Favipiravir significantly improved the latency to relief for pyrexia and cough. Adverse effects caused Favipiravir are mild and manageable. This trial is registered with Chictr.org.cn<br \/>\n(ChiCTR2000030254).<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.17.20037432v4 In a prospective, randomized, controlled, open-label multicenter trial involving 240 adult patients with COVID-19. Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7. Favipiravir&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/15-april-2020-favipiravir-significantly-improved-latency-to-relief-for-pyrexia-and-cough\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(15 April 2020) Favipiravir- significantly improved  latency to relief for pyrexia and cough&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/80"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=80"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/80\/revisions"}],"predecessor-version":[{"id":81,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/80\/revisions\/81"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=80"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=80"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=80"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}